Hypercalcemia of Malignancy in Adults

Publication Date: December 21, 2022

Key Points

Key Points

  • Hypercalcemia of malignancy (HCM), a condition associated with high morbidity and mortality, is the most common metabolic complication of malignancies.
  • All adults with HCM should receive treatment with denosumab (Dmab) or an intravenous (IV) bisphosphonate (BP).
  • Adults with calcitriol-mediated HCM should first be treated with glucocorticoids, with the addition of Dmab or an IV BP if glucocorticoid therapy is insufficient.

Treatment

...atment...

...tion 1In adults with HCM, Endocrine So...

...mendation 2In adults with HCM, ES suggests...

...ation 3In adults with severe HCM (serum calcium...

...In adults with refractory/recurrent HCM on a...

...ation 5In adults with HCM from tumors a...

...ion 6In adult patients with hypercalce...

...ommendation 7In adult patients with hyp...

...endation 8In adult patients with hype...


...Practice Statements...

...lts with HCM, adequate hydration with IV fluid...

...with HCM, dental hygiene and oral...

...ts with HCM who receive antiresorptive therapy,...

...S 4In adults with HCM, renal function (creatini...

...PS 5In adults with HCM and renal insuffi...

...dults with HCM, serum magnesium and pho...

...dults with HCM, clinical oncology consultatio...

...s with hypercalcemia due to parathyroid ca...


...able 1. Treatment Regimens for Hypercalcemia of Ma...


...ure 1. Suggested Workflow for the Ma...


...A: Common Terminology Criteria for Adverse Eve...